This study is for women diagnosed with urinary urgency incontinence (UUI) or overactive
bladder (OAB). Some patients continue to have symptoms even while taking medication for OAB.
The purpose of this study is to estimate the number of women who respond to a medication
called mirabegron and estimate change in symptom severity over 12 weeks of therapy. A
secondary goal is to correlate the female urinary microbiome (FUM) with response to treatment
and change in symptom severity over 12 weeks of therapy.